Bioceltix SA

NEW
FRA:XI3 (Poland)  
€ 20.4 (0%) Aug 21
At Loss
P/B:
6.55
Market Cap:
€ 102.46M ($ 119.75M)
Enterprise V:
€ 88.44M ($ 103.37M)
Volume:
0
Avg Vol (2M):
0
Trade In:

Business Description

Description
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
Name Current Vs Industry Vs History
Cash-To-Debt
258.69
Equity-to-Asset
0.96
Debt-to-EBITDA
-0.01
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate
-4.1
3-Year EPS without NRI Growth Rate
-3.9
3-Year FCF Growth Rate
-4.1
3-Year Book Growth Rate
106.6
Name Current Vs Industry Vs History
5-Day RSI
90.2
9-Day RSI
83.7
14-Day RSI
76.95
3-1 Month Momentum %
10.7
6-1 Month Momentum %
7.91
12-1 Month Momentum %
-13.25

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
22.56
Quick Ratio
22.56
Cash Ratio
21.07
Days Inventory
1.94
Days Payable
216.32

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-17.3
Shareholder Yield %
0.07

Profitability Rank

Name Current Vs Industry Vs History
ROE %
-36.74
ROA %
-34.29
ROIC %
-318.37
3-Year ROIIC %
-362.68
ROC (Joel Greenblatt) %
-432.65
ROCE %
-36.43

GF Value Rank

Name Current Vs Industry Vs History
Forward PE Ratio
8.37
PB Ratio
6.55
Price-to-Tangible-Book
6.54
EV-to-EBIT
-22.33
EV-to-EBITDA
-23.22
EV-to-FCF
-18.44
Price-to-Net-Current-Asset-Value 7.13
Price-to-Net-Cash 7.67
Earnings Yield (Greenblatt) %
-4.48
FCF Yield %
-4.68

Financials

FRA:XI3's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Bioceltix SA Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.79
Beta 0.8874
3-Year Sharpe Ratio 0.36
3-Year Sortino Ratio 0.64
Volatility % 60.83
14-Day RSI 76.95
14-Day ATR (€) 0.413782
20-Day SMA (€) 20.137
12-1 Month Momentum % -13.25
52-Week Range (€) 13.98 - 28.6
Shares Outstanding (Mil) 5.53

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Bioceltix SA Filings

Filing Date Document Date Form
No Filing Data

Bioceltix SA Stock Events

Financials Calendars
Event Date Price (€)
No Event Data

Bioceltix SA Frequently Asked Questions

What is Bioceltix SA(FRA:XI3)'s stock price today?
The current price of FRA:XI3 is €20.40. The 52 week high of FRA:XI3 is €28.60 and 52 week low is €13.98.
When is next earnings date of Bioceltix SA(FRA:XI3)?
The next earnings date of Bioceltix SA(FRA:XI3) is .
Does Bioceltix SA(FRA:XI3) pay dividends? If so, how much?
Bioceltix SA(FRA:XI3) does not pay dividend.

Press Release

Subject Date
No Press Release

Articles on Bioceltix SA

No articles.